Results 41 to 50 of about 1,034,274 (259)

Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis

Reumatismo, 2013
In axial spondyloarthritis (SpA), the efficacy of certolizumab pegol (CZP), a novel pegylated anti-tumor necrosis factor alpha drug has not been investigated.
A. Spadaro, A. Scarno, A. Carboni, F.M. Perrotta, C. Catalano, E. Lubrano, G. Valesini   +6 more
doaj   +1 more source

Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet, 2022
BACKGROUND Upadacitinib, a Janus kinase inhibitor, has been shown to be effective in patients with ankylosing spondylitis. We aimed to assess the efficacy and safety of upadacitinib in non-radiographic axial spondyloarthritis. METHODS The SELECT-AXIS 2
A. Deodhar, F. E. Van den Bosch, D. Poddubnyy, W. Maksymowych, D. M. van der Heijde, Taehun Kim, M. Kishimoto, R. Blanco, Yuan-Yuan Duan, Yihan Li, A. Pangan, P. Wung, I. Song   +12 more
semanticscholar   +1 more source

Spondyloarthritis associated with inflammatory myositis: An unusual case report

Indian Journal of Rheumatology, 2019
Spondyloarthritis is an inflammatory disorder of the axial skeleton, while inflammatory myositis is an inflammatory disease affecting the striated muscles. There is no usual association of spondyloarthritis and inflammatory myositis. A 35-year-old female
Pradip Kumar Prajapati
doaj   +1 more source

S100A4 is elevated in axial spondyloarthritis: a potential link to disease severity

BMC Rheumatology, 2020
Background S100A4 is a member of calcium binding S100 protein family well known for its role in cancer progression and metastasis. Nevertheless, S100A4 also serves as a negative regulator of bone formation. Dickkopf-1 (DKK-1), marker of bone remodelling,
Barbora Šumová, Lucie Andrés Cerezo, Hana Hulejová, Klára Prajzlerová, Michal Tomčík, Kristýna Bubová, Jan Štěpán, Mária Filková, Tereza Kropáčková, Mariam Grigorian, Karel Pavelka, Jiří Vencovský, Ladislav Šenolt   +12 more
doaj   +1 more source

Challenges in the diagnosis of axial spondyloarthritis.

Baillière's Best Practice & Research : Clinical Rheumatology, 2023
With back pain as one of the most common complaints in the population and with no single disease feature with sufficient sensitivity and specificity to diagnose axial spondyloarthritis (axSpA) on its own, diagnosing axSpA can be challenging.
F. V. van Gaalen, M. Rudwaleit
semanticscholar   +1 more source

Identification of gut dysbiosis in axial spondyloarthritis patients and improvement of experimental ankylosing spondyloarthritis by microbiome-derived butyrate with immune-modulating function

Frontiers in Immunology, 2023
Introduction Dysbiosis is an environmental factor that affects the induction of axial spondyloarthritis (axSpA) pathogenesis. In the present study, we investigated differences in the gut microbiota of patients with axSpA and revealed an association ...
H. Min, H. Na, Joo-Youn Jhun, Seon-Yeong Lee, S. Choi, G. Park, Jeong Su Lee, In Gyu Um, Seung Yoon Lee, Hochan Seo, Tae-Seop Shin, Yoon Kim, J. Lee, Seung-Ki Kwok, M. Cho, Sung-Hwan Park   +15 more
semanticscholar   +1 more source

Original paper Cytokine profiles in axial spondyloarthritis

, 2015
Objectives: Current studies concentrate on the cytokine network and its role in the pathogenesis of spondyloarthritis (SpA). In this study, we analyzed whether the serum cytokine profile (interleukins: IL-10, IL-11, IL-12, IL-15, IL-17, IL-23 and IL-33)
Marta Madej, Piotr Wiland, Beata Nowak, Arkadiusz Chlebicki, Lucyna Korman, Łukasz Lubiński, Jerzy Świerkot, Renata Sokolik, Patryk Woytala   +8 more
core   +1 more source

Elevating the Standard of Care for Patients with Axial Spondyloarthritis: ‘Calls to Action’ from Rheumacensus, a Multistakeholder Pan-European Initiative

Rheumatology and Therapy
Introduction Several barriers to optimal care in axial spondyloarthritis (axSpA) exist, which is detrimental to patient outcomes. The Rheumacensus programme aimed to identify how the standard of care (SoC) and treatment ambition for patients with axSpA ...
Andri Phoka, Bart J. F. van den Bemt, Ennio Lubrano, Inderjit Singh, Cristina Fernández-Carballido, Detlev Parow, Dale Webb, Fabienne Lacombe, Laura Harrington, Xenofon Baraliakos   +9 more
doaj   +1 more source

Real‐World Trends in Prenatal Antirheumatic Drug Utilization in Ontario, Canada: A Cross‐Sectional Time‐Series Analysis

Arthritis Care &Research, EarlyView.
Objective This study aimed to describe real‐world trends in preconception and prenatal use of antirheumatic drugs among pregnant individuals with rheumatic diseases in Ontario, Canada. Methods We conducted a time‐series analysis using repeated cross‐sectional data to examine annual patterns of disease‐modifying antirheumatic drug (DMARD) use among ...
Shenthuraan Tharmarajah, Swaleh Hussain, Sara J. T. Guilcher, Lisa M. McCarthy, Dharini Mahendira, Howard Berger, Mina Tadrous   +6 more
wiley   +1 more source

Axial spondyloarthritis: a new disease entity, not necessarily early ankylosing spondylitis.

, 2012
New classification criteria for axial spondyloarthritis have been developed with the goal of increasing sensitivity of criteria for early inflammatory spondyloarthritis. However these criteria substantially increase heterogeneity of the resulting disease
Robinson, P. C., Wordsworth, BP, Reveille, J. D., Brown, Matthew A., Robinson, PC, Wordsworth, B. P., Reveille, JD, Wordsworth, Bryan, Brown, MA   +8 more
core   +1 more source